US5079236A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use
Assignee: PRICEWATERHOUSECOOPERS Inc
•
Filing: 1987-05-27
•
Granted: 1992-01-07
•
Expires: 2007-05-27
Abstract
Abstract A heat stable, purified, pyrogen-free, heat sterilized fraction of hyaluronic acid suitable for use in formulations for intra-articular treatment of animals which includes minor amounts of sulphated mucopolysaccharides, sulphated ash, chlorides, solvents and less than 0.6% protein, having a molecular weight of less than 750,000 and exhibiting a specific absorbance of a 1% solution at A257nm of less than 3. A formulation for intra-articular treatment of animals including an aqueous solution of the heat stable fraction of hyaluronic acid and preservatives, such as sodium benzoate, methylparaben and propylparaben, having a pH of 6.8-8.0 at 25° C. A method of preparing a formulation for intra-articular treatment of animals involving adding and dissolving methyl parahydroxybenzoate, propyl parahydroxybenzoate and sodium benzoate in hot water, mixing the preservative solution to dissolve the parabens, adding sodium hyaluronate in the solution, adjusting the pH of the resultant solution to 6.8-8.0 and diluting with water to a final volume prior to filling suitable dosages for intra-articular treatment of animals into vials which are autoclaved to sterilize the aqueous formulation. An intra-articular treatment involving injecting a suitable dosage of an aqueous solution containing a heat stable, purified, pyrogen-free, heat-sterilized fraction of hyaluronic acid into a joint of an animal suffering from a degenerative joint disease.
Inventors
- 👤 Alan Drizen
- 👤 Anita Aviad
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 22:43
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K31/726; A61K31/728; A61K47/00; A61K47/30; A61K47/36; A61K9/00; A61K9/0012; A61K9/0019; A61K2300/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
192 words
A method for the intra-articular treatment of animals, which comprises: injecting a therapeutically effective dosage of a solution of a heat stable, purified, pyrogen-free, heat sterilized fraction of a sodium salt of hyaluronic acid having an average molecular weight within the range of 50,000 to 200,000 into a joint of an animal suffering from a degenerative joint disease, wherein said solution has a pH within the range of about 6.8-8.0 at 25° C., a specific absorbance of a 1% solution of 1.5 to 3, and comprises on a total weight basis: (i) 97 to 102% sodium hyaluronate; (ii) about 1% sulphated mucopolysaccharides; (iii) about 0.4% albumin; (iv) about 15 to 19% sulphated ash; (v) about 2% sodium chloride; and (vi) about 4% solvents selected from the group consisting of acetone, ethanol, and mixtures thereof; a preservative comprising, per milliliter of final solution a mixture of 0.41 to 0.5 milligrams sodium benzoate, 0.86 to 1.2 milligrams methylparaben, and 0.043 to 0.06 milligrams propylparaben; and water in a dosage form containing said heat stable, purified, pyrogen-free, heat sterilized hyaluronic acid in an amount within the range of 10 mg/ml solution to 20 mg/ml solution.
Claim 2
Independent Claim
192 words
A method for the intra-articular treatment of animals, which comprises: injecting a therapeutically effective dosage of a solution of a heat stable, purified, pyrogen-free, heat sterilized fraction of a sodium salt of hyaluronic acid having an average molecular weight within the range of 50,000 to 200,000 into a joint of an animal suffering from a degenerative joint disease, wherein said solution has a pH within the range of about 6.8-8.0 at 25° C., a specific absorbance of a 1% solution of 1.5 to 3, and comprises on a total weight basis: (i) 97 to 102% sodium hyaluronate; (ii) about 1% sulphated mucopolysaccharides; (iii) about 0.4% albumin; (iv) about 15 to 19% sulphated ash; (v) about 2% sodium chloride; and (vi) about 4% solvents selected from the group consisting of acetone, ethanol, and mixtures thereof; a preservative comprising, per milliliter of final solution a mixture of 0.41 to 0.5 milligrams sodium benzoate, 0.86 to 1.2 milligrams methylparaben, and 0.043 to 0.06 milligrams propylparaben; and water in a dosage form containing said heat stable, purified, pyrogen-free, heat sterilized hyaluronic acid in an amount within the range of 10 mg/ml solution to 20 mg/ml solution.
Claim 3
Independent Claim
192 words
A method for the intra-articular treatment of animals, which comprises: injecting a therapeutically effective dosage of a solution of a heat stable, purified, pyrogen-free, heat sterilized fraction of a sodium salt of hyaluronic acid having an average molecular weight within the range of 75,000 to 150,000 into a joint of an animal suffering from a degenerative joint disease, wherein said solution has a pH within the range of about 6.8-8.0 at 25° C., a specific absorbance of a 1% solution of 1.5 to 3, and comprises on a total weight basis: (i) 97 to 102% sodium hyaluronate; (ii) about 1% sulphated mucopolysaccharides; (iii) about 0.4% albumin; (iv) about 15 to 19% sulphated ash; (v) about 2% sodium chloride; and (vi) about 4% solvents selected from the group consisting of acetone, ethanol, and mixtures thereof; a preservative comprising, per milliliter of final solution, a mixture of 0.41 to 0.5 milligrams sodium benzoate, 0.86 to 1.2 milligrams methylparaben, and 0.043 to 0.06 milligrams propylparaben; and water in a dosage form containing said heat stable, purified, pyrogen-free, heat sterilized hyaluronic acid in an amount within the range of 10 mg/ml solution to 20 mg/ml solution.
Claim 4
Independent Claim
192 words
A method for the intra-articular treatment of animals, which comprises: injecting a therapeutically effective dosage of a solution of a heat stable, purified, pyrogen-free, heat sterilized fraction of a sodium salt of hyaluronic acid having an average molecular weight within the range of 75,000 to 150,000 into a joint of an animal suffering from a degenerative joint disease, wherein said solution has a pH within the range of about 6.8-8.0 at 25° C., a specific absorbance of a 1% solution of 1.5 to 3, and comprises on a total weight basis: (i) 97 to 102% sodium hyaluronate; (ii) about 1% sulphated mucopolysaccharides; (iii) about 0.4% albumin; (iv) about 15 to 19% sulphated ash; (v) about 2% sodium chloride; and (vi) about 4% solvents selected from the group consisting of acetone, ethanol, and mixtures thereof; a preservative comprising, per milliliter of final solution, a mixture of 0.41 to 0.5 milligrams sodium benzoate, 0.86 to 1.2 milligrams methylparaben, and 0.043 to 0.06 milligrams propylparaben; and water in a dosage form containing said heat stable, purified, pyrogen-free, heat sterilized hyaluronic acid in an amount within the range of 10 mg/ml solution to 20 mg/ml solution.
Claim 5
Independent Claim
188 words
A method for the intra-articular treatment of animals, which comprises: injecting a therapeutically effective dosage of a solution of a heat stable, purified, pyrogen-free, heat sterilized fraction of a sodium salt of hyaluronic acid having an average molecular weight of about 150,000 into a joint of an animal suffering from a degenerative joint disease, wherein said solution has a pH within the range of about 6.8-8.0 at 25° C., a specific absorbance of a 1% solution of 1.5 to 3, and comprises on a total weight basis: (i) 97 to 102% sodium hyaluronate; (ii) about 1% sulphated mucopolysaccharides; (iii) about 0.4% albumin; (iv) about 15 to 19% sulphated ash; (v) about 2% sodium chloride; and (vi) about 4% solvents selected from the group consisting of acetone, ethanol, and mixtures thereof; a preservative comprising, per milliliter of final solution, a mixture of 0.41 to 0.5 milligrams sodium benzoate, 0.86 to 1.2 milligrams methylparaben, and 0.043 to 0.06 milligrams propylparaben; and water in a dosage form containing said heat stable, purified, pyrogen-free, heat sterilized hyaluronic acid in an amount within the range of 10 mg/ml solution to 20 mg/ml solution.
Claim 6
Independent Claim
188 words
A method for the intra-articular treatment of animals, which comprises: injecting a therapeutically effective dosage of a solution of a heat stable, purified, pyrogen-free, heat sterilized fraction of a sodium salt of hyaluronic acid having an average molecular weight of about 150,000 into a joint of an animal suffering from a degenerative joint disease, wherein said solution has a pH within the range of about 6.8-8.0 at 25° C., a specific absorbance of a 1% solution of 1.5 to 3, and comprises on a total weight basis: (i) 97 to 102% sodium hyaluronate; (ii) about 1% sulphated mucopolysaccharides; (iii) about 0.4% albumin; (iv) about 15 to 19% sulphated ash; (v) about 2% sodium chloride; and (vi) about 4% solvents selected from the group consisting of acetone, ethanol, and mixtures thereof; a preservative comprising, per milliliter of final solution, a mixture of 0.41 to 0.5 milligrams sodium benzoate, 0.86 to 1.2 milligrams methylparaben, and 0.043 to 0.06 milligrams propylparaben; and water in a dosage form containing said heat stable, purified, pyrogen-free, heat sterilized hyaluronic acid in an amount within the range of 10 mg/ml solution to 20 mg/ml solution.
Claim 7
Independent Claim
188 words
A method for the intra-articular treatment of animals, which comprises: injecting a therapeutically effective dosage of a solution of a heat stable, purified, pyrogen-free, heat sterilized fraction of a sodium salt of hyaluronic acid having an average molecular weight of about 75,000 into a joint of an animal suffering from a degenerative joint disease, wherein said solution has a pH within the range of about 6.8-8.0 at 25° C., a specific absorbance of a 1% solution of 1.5 to 3, and comprises on a total weight basis: (i) 97 to 102% sodium hyaluronate; (ii) about 1% sulphated mucopolysaccharides; (iii) about 0.4% albumin; (iv) about 15 to 19% sulphated ash; (v) about 2% sodium chloride; and (vi) about 4% solvents selected from the group consisting of acetone, ethanol, and mixtures thereof; a preservative comprising, per milliliter of final solution, a mixture of 0.41 to 0.5 milligrams sodium benzoate, 0.86 to 1.2 milligrams methylparaben, and 0.043 to 0.06 milligrams propylparaben; and water in a dosage form containing said heat stable, purified, pyrogen-free, heat sterilized hyaluronic acid in an amount within the range of 10 mg/ml solution to 20 mg/ml solution.
Claim 8
Independent Claim
188 words
A method for the intra-articular treatment of animals, which comprises: injecting a therapeutically effective dosage of a solution of a heat stable, purified, pyrogen-free, heat sterilized fraction of a sodium salt of hyaluronic acid having an average molecular weight of about 75,000 into a joint of an animal suffering from a degenerative joint disease, wherein said solution has a pH within the range of about 6.8-8.0 at 25° C., a specific absorbance of a 1% solution of 1.5 to 3, and comprises on a total weight basis: (i) 97 to 102% sodium hyaluronate; (ii) about 1% sulphated mucopolysaccharides; (iii) about 0.4% albumin; (iv) about 15 to 19% sulphated ash; (v) about 2% sodium chloride; and (vi) about 4% solvents selected from the group consisting of acetone, ethanol, and mixtures thereof; a preservative comprising, per milliliter of final solution, a mixture of 0.41 to 0.5 milligrams sodium benzoate, 0.86 to 1.2 milligrams methylparaben, and 0.043 to 0.06 milligrams propylparaben; and water in a dosage form containing said heat stable, purified, pyrogen-free, heat sterilized hyaluronic acid in an amount within the range of 10 mg/ml solution to 20 mg/ml solution.
References Cited (Backward Citations)
US2585546A
Cited
US3396081A
Cited
US3862003A
Cited
US4141973B1
Cited
US4141973A
Cited
JPS5613489A
Cited
US4303676A
Cited
US4517296A
Cited
US4517295A
Cited
CA1205031A
Cited
EP0144019A2
Cited
US4782046A
Cited
US4629623A
Cited
US4801619A
Cited
EP0239335A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-01-06 | 1995-07-08 | 1996-01-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-01-06 | 1999-07-08 | 2000-01-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-01-06 | 2003-07-08 | 2004-01-07 | $7700.00 | Window Closed / Lapsed |